TUMOR MUTATIONAL BURDEN (TMB) IS A POTENTIAL PREDICTOR OF RESPONSE TO IMMUNE CHECKPOINT INHIBITORS (ICI) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)

Authors

  • Romualdo Barroso-Sousa Dana-Farber Cancer Institute
  • Svitlana Tyekucheva Dana-Farber Cancer Institute
  • Pedro Exman Dana-Farber Cancer Institute
  • Renato Umeton Dana-Farber Cancer Institute
  • F. Stephen Hodi Dana-Farber Cancer Institute
  • Eric P. Winer Dana-Farber Cancer Institute
  • Nancy U Lin Dana-Farber Cancer Institute
  • Sara M. Tolaney Dana-Farber Cancer Institute

DOI:

https://doi.org/10.29289/259453942019v29s1g04

Downloads

Download data is not yet available.

Downloads

Published

2019-09-29

How to Cite

Barroso-Sousa, R., Tyekucheva, S., Exman, P., Umeton, R., Hodi, F. S., Winer, E. P., … Tolaney, S. M. (2019). TUMOR MUTATIONAL BURDEN (TMB) IS A POTENTIAL PREDICTOR OF RESPONSE TO IMMUNE CHECKPOINT INHIBITORS (ICI) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC). Mastology, 29(3), 5. https://doi.org/10.29289/259453942019v29s1g04

Issue

Vol. 29 No. 3 (2019): Supplement 1

Section

Geral

License

Copyright (c) 2019 Romualdo Barroso-Sousa, Svitlana Tyekucheva, Pedro Exman, Renato Umeton, F. Stephen Hodi, Eric P. Winer, Nancy U Lin, Sara M. Tolaney

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.